The Executive Board of Stada Arzneimittel AG has published the final figures for financial year 2016 which are, due to the revaluation of a transaction, diferent from the preliminary figures which the company had already published on March 1, 2017.
Stada has reported net income down 22 percent to €85.9 million (previous year: €110.4 million).
“Despite extensive reorganization work, we were not only able to increase earnings by a substantial margin in some areas in 2016, we also slightly surpassed the original forecast for the past financial year in all key figures. This shows that we deliver on our promises, even in difficult times”, said STADA’s Chairman of the Executive Board Dr. Matthias Wiedenfels.
“With our future program STADA Plus, we laid the foundations for further strategic development last year and initiated important measures to increase our profitability. We are transforming STADA into a company that is strong, agile and viable for the future. This gives us the confidence to take on more ambitious goals than six months ago: we will increase our operating profit by nearly 50% in just three years!” Wiedenfels added